NASH News & Notes From The European Liver Meeting
Executive Summary
Non-alcoholic steatohepatitis (NASH) was a focal point of EASL’s conference. Madrigal becomes the fifth company into Phase III in NASH, but Viking’s competing THR agonist is progressing also.
You may also be interested in...
Madrigal Solidifies Presumed NASH Lead With 52-Week Data
Full-year findings for resmetirom reported at EASL confirm 16-week data in non-alcoholic steatohepatitis presented in 2020. Analysts say these data continue to de-risk the drug, but more important readouts await.
Terns Says Phase IIa Data Show Superior NASH Safety Profile In FXR Class
TERN-101 showed a superior safety and tolerability profile for lipid levels and pruritis compared to other FXR agonists in a mid-stage study. Terns is now looking to a NASH combo study with its THR beta agonist.
Viking Phase II Update Shows Sustained Response After Treatment’s End
Currently running a Phase IIb NASH trial with VK2809, Viking reported at EASL that 16-week data in a Phase II study of NAFLD patients showed sustained liver fat reduction after treatment ended.